Interaction of drug- and granulocyte-mediated killing of Pseudomonas aeruginosa in a murine pneumonia model.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Journal of Infectious Diseases

• Publication date

  2014-10-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1093/infdis/jiu237PMID 24760199PMCID PMC4271070
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Impact of Meropenem in Combination with Tobramycin in a Murine Model of Pseudomonas aeruginosa Pneumonia

  2013cited by this paper
• Inadequate treatment of ventilator-associated and hospital-acquired pneumonia: Risk factors and impact on outcomes

  2012cited by this paper
• Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin

  2012cited by this paper
• Penetration of Meropenem into Epithelial Lining Fluid of Patients with Ventilator-Associated Pneumonia

  2011cited by this paper
• Resistance Emergence Mechanism and Mechanism of Resistance Suppression by Tobramycin for Cefepime for Pseudomonas aeruginosa

  2011cited by this paper
• Saturability of Granulocyte Kill of Pseudomonas aeruginosa in a Murine Model of Pneumonia

  2011cited by this paper
• Meropenem Penetration into Epithelial Lining Fluid in Mice and Humans and Delineation of Exposure Targets

  2011cited by this paper
• The Combination of Meropenem and Levofloxacin Is Synergistic with Respect to both Pseudomonas aeruginosa Kill Rate and Resistance Suppression

  2010cited by this paper
• Impact of Burden on Granulocyte Clearance of Bacteria in a Mouse Thigh Infection Model

  2010cited by this paper
• Feedback dose alteration significantly affects probability of pathogen eradication in nosocomial pneumonia

  2009cited by this paper
• Efficacy of Bilateral Bronchoalveolar Lavage for Diagnosis of Ventilator-Associated Pneumonia

  2009influential reference
• Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : Approved standard

  2006cited by this paper
• Gram-negative bacterial pneumonia: aetiology and management

  2006cited by this paper
• Antimicrobial treatment of hospital-acquired pneumonia.

  2005cited by this paper
• Effective Antimicrobial Regimens for Use in Humans for Therapy of Bacillus anthracis Infections and Postexposure Prophylaxis

  2005cited by this paper
• Appropriate Empiric Antimicrobial Therapy of Nosocomial Pneumonia: The Role of the Carbapenems

  2004cited by this paper
• Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia.

  2003cited by this paper
• Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial.

  2003cited by this paper
• Antimicrobial treatment of hospital-acquired pneumonia.

  2003cited by this paper
• Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit

  1996influential reference
• Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group

  1994cited by this paper
• Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. Impact of plasma concentrations, organism, minimum inhibitory concentration, and clinical condition on bacterial eradication.

  1989cited by this paper

• Comparison of the in vivo efficacy and resistance development potential between cefiderocol and ceftolozane/tazobactam human simulated exposures against Pseudomonas aeruginosa in 72-hour murine thigh infection model

  2025cites this paper
• Application of LAPM and ABM methods to a fractional SCIR model of pneumonia diseases

  2025cites this paper
• Comparative In Vitro Killing of Key Bovine Respiratory Bacterial Pathogens by Pradofloxacin and Eight Other Veterinary Antimicrobial Agents

  2025cites this paper
• Impact of Fractal-Fractional Dynamics on Pneumonia Transmission Modeling

  2025cites this paper
• Improved characterization of aminoglycoside penetration into human lung epithelial lining fluid via population pharmacokinetics

  2024cites this paper
• Confirming the Suitability of a Gentamicin Dosing Strategy in Neonates Using the Population Pharmacokinetic Approach with Truncated Sampling Duration

  2024cites this paper
• Dose regimen optimization of cephalothin for surgical prophylaxis against Staphylococcus aureus and coagulase negative staphylococci in dogs by pharmacokinetic/pharmacodynamic modeling.

  2024cites this paper
• Population pharmacokinetics and humanized dosage regimens matching the peak, area, trough, and range of amikacin plasma concentrations in immune-competent murine bloodstream and lung infection models

  2024cites this paper
• Model-Informed Dose Optimisation of Polymyxin-Rifampicin Combination Therapy against Multidrug-Resistant Acinetobacter baumannii.

  2023cites this paper
• Evaluation of Fosfomycin-Sulbactam Combination Therapy against Carbapenem-Resistant Acinetobacter baumannii Isolates in a Hollow-Fibre Infection Model

  2022cites this paper
• Use of pharmacokinetic/pharmacodynamic approaches for dose optimization: a case study of plazomicin.

  2022cites this paper
• Pharmacodynamics of Piperacillin-Tazobactam/Amikacin Combination versus Meropenem against Extended-Spectrum β-Lactamase-Producing Escherichia coli in a Hollow Fiber Infection Model

  2022cites this paper
• The ingredients for an antimicrobial mathematical modelling broth.

  2022cites this paper
• Pharmacodynamic evaluation of piperacillin/tazobactam versus meropenem against extended-spectrum β-lactamase-producing and non-producing Escherichia coli clinical isolates in a hollow-fibre infection model

  2022cites this paper
• Pharmacodynamic evaluation of piperacillin/tazobactam against extended-spectrum β-lactamase-producing versus non-producing Escherichia coli in a hollow-fibre infection model.

  2022cites this paper
• Analysis of Pneumonia Model via Efficient Computing Techniques

  2022cites this paper
• Pharmacodynamics of ceftriaxone for the treatment of methicillin-susceptible Staphylococcus aureus: Is it a viable treatment option?

  2022cites this paper
• Model‐Informed Drug Development for Anti‐Infectives: State of the Art and Future

  2021cites this paper
• Evaluating Mono- and Combination Therapy of Meropenem and Amikacin against Pseudomonas aeruginosa Bacteremia in the Hollow-Fiber Infection Model

  2021cites this paper
• Tissue compartmentalization enables Salmonella persistence during chemotherapy

  2021cites this paper
• PK/PD Analysis by Nonlinear Mixed-Effects Modeling of a Marbofloxacin Dose Regimen for Treatment of Goat Mastitis Produced by Coagulase-Negative Staphylococci

  2021cites this paper
• Effects of Growth Medium and Inoculum Size on Pharmacodynamics Activity of Marbofloxacin against Staphylococcus aureus Isolated from Caprine Clinical Mastitis

  2021cites this paper
• Modeling the transmission dynamics of delayed pneumonia-like diseases with a sensitivity of parameters

  2021cites this paper
• Generating Genotype-Specific Aminoglycoside Combinations with Ceftazidime/Avibactam for KPC-Producing Klebsiella pneumoniae

  2021cites this paper
• Semi-mechanistic PK/PD modelling of meropenem and sulbactam combination against carbapenem-resistant strains of Acinetobacter baumannii

  2021cites this paper
• Present and Future Perspectives on Therapeutic Options for Carbapenemase-Producing Enterobacterales Infections

  2021cites this paper
• Impact of the Epithelial Lining Fluid Milieu on Amikacin Pharmacodynamics Against Pseudomonas aeruginosa

  2021influential citation
• Pharmacodynamics of once- versus twice-daily dosing of nebulized amikacin in an in vitro Hollow-Fiber Infection Model against 3 clinical isolates of Pseudomonas aeruginosa.

  2021cites this paper
• Semimechanistic Pharmacokinetic/Pharmacodynamic Modeling of Fosfomycin and Sulbactam Combination against Carbapenem-Resistant Acinetobacter baumannii

  2021cites this paper
• Combating Multidrug‐Resistant Bacteria by Integrating a Novel Target Site Penetration and Receptor Binding Assay Platform Into Translational Modeling

  2021cites this paper
• Pivotal Role of Translation in Anti‐Infective Development

  2021cites this paper
• Pharmacodynamic Evaluation of Plasma and Epithelial Lining Fluid Exposures of Amikacin against Pseudomonas aeruginosa in a Dynamic In Vitro Hollow-Fiber Infection Model

  2020cites this paper
• Combination of polymyxin B and minocycline against multidrug-resistant Klebsiella pneumoniae: interaction quantified by pharmacokinetic-pharmacodynamic modelling from in vitro data.

  2020cites this paper
• Effect of drug dose and timing of treatment on the emergence of drug resistance in vivo in a malaria model

  2020cites this paper
• Developing New Drugs for Mycobacterium tuberculosis Therapy: What Information Do We Get from Preclinical Animal Models?

  2020cites this paper
• Is it time to move away from polymyxins?: evidence and alternatives

  2020cites this paper
• Plazomicin: A Novel Aminoglycoside for the Treatment of Resistant Gram-Negative Bacterial Infections

  2019cites this paper
• Generating Robust and Informative Nonclinical In Vitro and In Vivo Bacterial Infection Model Efficacy Data To Support Translation to Humans

  2019cites this paper
• Breakpoint determination when multiple organisms are tested for effect targets

  2019cites this paper
• Individualising Therapy to Minimize Bacterial Multidrug Resistance

  2018cites this paper
• Optimization and Evaluation of Piperacillin-Tobramycin Combination Dosage Regimens against Pseudomonas aeruginosa for Patients with Altered Pharmacokinetics via the Hollow-Fiber Infection Model and Mechanism-Based Modeling

  2018cites this paper
• Antibiotic selection in the treatment of acute invasive infections by Pseudomonas aeruginosa: Guidelines by the Spanish Society of Chemotherapy

  2018cites this paper
• Differences in suppression of regrowth and resistance despite similar initial bacterial killing for meropenem and piperacillin/tazobactam against Pseudomonas aeruginosa and Escherichia coli.

  2018cites this paper
• Antibacterial Activity of Human Simulated Epithelial Lining Fluid Concentrations of Ceftazidime-Avibactam Alone or in Combination with Amikacin Inhale (BAY41-6551) against Carbapenem-Resistant Pseudomonas aeruginosa and Klebsiella pneumoniae

  2018cites this paper
• Efficacy of Human-Simulated Exposures of Ceftolozane-Tazobactam Alone and in Combination with Amikacin or Colistin against Multidrug-Resistant Pseudomonas aeruginosa in an In Vitro Pharmacodynamic Model

  2018cites this paper
• Elucidation of the pharmacokinetic/pharmacodynamic determinants of fosfomycin activity against Pseudomonas aeruginosa using a dynamic in vitro model

  2018cites this paper
• Balancing Antibacterial Efficacy and Reduction in Renal Function to Optimise Initial Gentamicin Dosing in Paediatric Oncology Patients

  2017cites this paper
• TDtest: easy detection of bacterial tolerance and persistence in clinical isolates by a modified disk-diffusion assay

  2017cites this paper
• In vivo infection models in the pre‐clinical pharmacokinetic/pharmacodynamic evaluation of antimicrobial agents

  2017cites this paper
• Evaluation of Pharmacokinetic/Pharmacodynamic Model-Based Optimized Combination Regimens against Multidrug-Resistant Pseudomonas aeruginosa in a Murine Thigh Infection Model by Using Humanized Dosing Schemes

  2017cites this paper
• Biofilms and host response – helpful or harmful

  2017cites this paper
• Dilution Factor of Quantitative Bacterial Cultures Obtained by Bronchoalveolar Lavage in Patients with Ventilator-Associated Bacterial Pneumonia

  2017influential citation
• Combination Chemotherapy With Anti-Infective Agents

  2017cites this paper
• Phagocytes, Antibiotics, and Self-Limiting Bacterial Infections.

  2017cites this paper
• Natural History of Francisella tularensis in Aerosol-Challenged BALB/c Mice

  2016cites this paper
• Paradoxical Effect of Polymyxin B: High Drug Exposure Amplifies Resistance in Acinetobacter baumannii

  2016cites this paper
• Colistin and Polymyxin B Dosage Regimens against Acinetobacter baumannii: Differences in Activity and the Emergence of Resistance

  2016cites this paper
• Optimization of synergistic combination regimens against carbapenem-1 and aminoglycoside-resistant clinical Pseudomonas aeruginosa isolates 2 via mechanism-based pharmacokinetic / pharmacodynamic modeling 3 4

  2016cites this paper
• Effect of different renal function on antibacterial effects of piperacillin against Pseudomonas aeruginosa evaluated via the hollow-fibre infection model and mechanism-based modelling.

  2016cites this paper
• From lead optimization to NDA approval for a new antimicrobial: Use of pre-clinical effect models and pharmacokinetic/pharmacodynamic mathematical modeling.

  2016cites this paper
• Optimization of Synergistic Combination Regimens against Carbapenem- and Aminoglycoside-Resistant Clinical Pseudomonas aeruginosa Isolates via Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling

  2016cites this paper
• Polymyxin Resistance in Acinetobacter baumannii: Genetic Mutations and Transcriptomic Changes in Response to Clinically Relevant Dosage Regimens

  2016cites this paper
• Suppression of Emergence of Resistance in Pathogenic Bacteria: Keeping Our Powder Dry, Part 1

  2015cites this paper
• Novel Approach To Optimize Synergistic Carbapenem-Aminoglycoside Combinations against Carbapenem-Resistant Acinetobacter baumannii

  2015cites this paper
• Update on ventilator-associated pneumonia

  2015cites this paper
• Combination treatment with meropenem plus levofloxacin is synergistic against Pseudomonas aeruginosa infection in a murine model of pneumonia.

  2015influential citation
• Bacteriostatic versus bactericidal antibiotics for patients with serious bacterial infections: systematic review and meta-analysis.

  2015cites this paper
• Augmented renal clearance and therapeutic monitoring of β-lactams.

  2015cites this paper
• Meropenem plus Levofloxacin is Synergistic for the Therapy of Pseudomonas aeruginosa as Tested in a Murine Model of Pneumonia

  2014cites this paper
• Anti-Pseudomonas aeruginosa IgY antibodies augment bacterial clearance in a murine pneumonia model.

  2014cites this paper